<p><strong>Initial Treatment of Advanced Ovarian Carcinoma</strong>: Carboplatin is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimenconsists of Carboplatin and cyclophosphamide. Two randomizedcontrolled studies conducted by the NCIC and SWOG with carboplatin versus&nbsp;cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups.<br />
<br />
There is limited statistical power to demonstrate equivalence in overal&nbsp; pathologic complete response rates and long-term survival ( &ge; 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor&nbsp;&lt; 2 cm after initial&nbsp;surgery&nbsp;also limits the statistical power to demonstrate equivalence in this subgroup.<br />
<br />
<strong>Secondary Treatment of Advanced Ovarian Carcinoma</strong>: Carboplatin is indicated for the&nbsp;palliative treatment&nbsp;of patients with ovarian carcinoma recurrent after prior&nbsp;chemotherapy, including patients who have been previously treated with cisplatin.<br />
<br />
Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin&nbsp;therapy&nbsp;may have a decreased response rate.</p>